Screening for renal disease and other chronic diseases in Aboriginal adults and preliminary experience of a medical intervention program

Nephrology

Volumn 4, Issue SUPPL., 1998, Pages

  Hoy, Wendy ^a,b  

^a ROYAL DARWIN HOSPITAL   (Australia)

^b MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABORIGINE; CONFERENCE PAPER; DIAGNOSTIC VALUE; HUMAN; KIDNEY DISEASE; PRIORITY JOURNAL; PROTEINURIA; RISK FACTOR; SCREENING TEST;

EID: 0032468923     PISSN: 13205358     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1797.1998.tb00481.x     Document Type: Conference Paper

References (38)

1. Cunningham J, Condon JR. Premature morrality in Aboriginal adults in the Northern Territory, 1979-1991. Med. J. Aust. 1996; 165: 309-12.
2. Hoy WE, Norman RJ, Hayhurst BG, Pugsley DJ. A brief health profile of adults in a Northern Territory Aboriginal community, with an emphasis on preventable morbidities. Aust. NZ J. Public Health 1997; 21: 121-6.
3. Hoy WE. Towards an epidemiological definition of renal disease: Rates and associations of albuminuria in a high-risk Australian Aboriginal community. Nephrology 1998; 4: S59-S65.
4. Nathan DM, Rosenbaum C, Protasowicki VD. Single void urine samples can be used to estimate quantitative microalbuminuria. Diabetes Care 1987; 10:, 414-18.
5. Lemann J, Doumas BT. Proteinuria in health and disease assessed by using the urinary protein/creatinine ratio. Clin. Chem. 1987; 33: 297-9.
6. Woolerton J, Jury DR, Dunn PJ et al. Urine albumin creatinine ratio and clinical correlates in a diabetic population. NZ Med. J. 1987; 100: 130-4
7. Nelson RG, Knowler WC, Pettitt DJ et al. Assessment of risk of overt nephropathy in diabetic patients from albumin excretion in untimed urine specimens. Arch. Intern. Med. 1991; 151: 1761-5.
8. Consensus Statement. Preventing the kidney disease of diabetes mellitus: Public health perspectives. Am. J. Kidney Dis. 1989; XIII: 2-6.
9. Bangstad HJ, Dahl Jorgensen K, Kjaersgaard R et al. Urinary albumin excretion rate and puberty in nondiabetic children and adolescents. Acta. Paediatr. 1993; 82: 857-62.
10. Guest CS, Ratnaike S, Larkins RG. Albuminuria in Aborigines and Europids of south-eastern Australia. Med. J. Aust. 1993; 159: 335-8.
11. Viberti GC. Interventions based on microalbuminuria screening and low protein diet in the treatment of kidney disease of diabetes mellitus. Am. J. Kidney Dis. 1989; XIII: 41-4.
12. Collins VR, Dowse GK, Finch CF et al. Prevalence and risk factors for micro- and macroalbuminuria in diabetic subjects and entire population of Nauru. Diabetes 1989; 38: 1602-10.
13. Mogensen CE, Hansen KW, Sommer S et al. Microalbuminuria: studies in diabetes, essential hypertension and renal diseases as compared with the background population. Adv. Nephrol. Necker Hosp. 1991; 20: 191-228.
14. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity onset diabetes. N. Engl. J. Med. 1984; 310: 356-60.
15. Nelson RG, Pettitt DJ, Carraher MJ et al. Effect of proteinuria on mortality in NIDDM. Diabetes 1988; 37: 1499-504.
16. Schmitz A, Vaeth M. Microalbuminuria: A major risk factor in noninsulin dependent diabetes: A 10 year follow up study of 503 patients. Diabet. Med. 1988; 5: 126-34.
17. Mattock MB, Morrish NJ, Viberti G et al. Prospective study of microalbuminuria as predictor of mortality in NIDDM. Diabetes 1992; 41: 736-41.
18. Yudkin JS, Forrest RD, Jackson CA. Microalbuminuria as a predictor of vascular disease in non-diabetic subjects. Lancet 1988; ii: 530-3.
19. Damsgaard EM, Froland A, Jorgensen OD et al. Microalbuminuria as predictor of increased mortality in elderly people. BMJ 1990; 300: 297-300.
20. Reaven GM. Insulin resistance and compensatory hyperinsulinemia; role in hypertension, dyslipidemia and coronary artery disease. Am. Heart J. 1992; 121: 1283-8.
21. O'Dea K. Diabetes in Aboriginal Australians. Curr. Ther. 1996; 25-8.
22. Barker DJP. Mothers and Babies and Disease in Later Life, BMJ Publishing Group, Tavistock Square, 1994.
23. The Fifth Report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. Arch. Intern. Med. 1993; 153: 154-84.
24. Mogensen CE, Keane WF, Bennett PH et al. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 1995; 346: 1080-4.
25. Lewis EJ, Hunsicker LG, Bain RP et al. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N. Engl. J. Med. 1993; 329: 1456-62.
26. Laffel L, McGill JB, Gans DJ, on behalf of the North American Microalbuminuria Study Group. The beneficial effect of angiotensin converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. Am. J. Med. 1995; 99: 497-504.
27. Ravid M, Savin H, Lang R et al. Proteinuria, renal impairment, metabolic control, and blood pressure in type 2 diabetes mellitus: A 14 year follow up report on 195 patients. Arch. Intern. Med. 1992; 152: 1225-9.
28. Ravid M, Savin H, Jutrin I et al. Long-term stabilizing effect of angiotensin converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type 2 diabetic patients. Ann. Intern. Med. 1993; 118: 577-81.
29. Bianchi S, Bigazzi R, Baldari G et al. Microalbuminuria in patients with essential hypertension: effects of several antihypertensive drugs. Am. J. Med. 1992; 93: 525-8.
30. Rosenberg ME, Hostetter TH. Comparative effects of antihypertensives on proteinuria: angiotensin converting enzyme inhibitors versus alpha 1 anatagonist. Am. J. Kidney Dis. 1991; XVIII: 472-82.
31. Ihle B, Becker G, Whitworth J et al. The effect of angiotensin converting enzyme inhibition on progression of chronic renal insufficiency. J. Am. Soc. Nephrol. 1992; 3: 284.
32. Bedogna V, Valvo E, Casagrande P et al. Effect of ACE inhibition in normotensive patients with chronic glomerular disease and normal renal function. Kidney Int. 1994; 38: 101-7.
33. Gansevoort RT, de Zeeuw D, de Jong PE. Long-term benefits of the antiproteinuric effect of angiotensin converting enzyme inhibition in nondiabetic renal disease. Am. J. Kidney Dis. 1993; 202-6.
34. Toto R, Mitchell H, Smith R et al. Aggressive blood pressure control with enalapril or conventional therapy preserves renal function in inner city Blacks with severe hypertensive nephrosclerosis. Am. J. Hypertens. 1993; 6: A5-6.
35. Zuchelli P, Zuccala A, Borghi M et al. Long term comparison between captropril and nifedipine in the progression of renal insufficiency. Kidney Int. 1992; 42: 452-6.
36. Cattran DC, Greenwood C, Ritchie S. Long term benefits of angiotensin converting enzyme inhibitor therapy in patients with severe immunoglobulin A nephropathy: a comparison to patients receiving treatment with other antihypertensive agents and patients receiving no therapy. Am. J. Kidney Dis. 1994; 23: 247-54.
37. Maschio G, Alberti D, Janin G et al. Effect of angiotensin converting enzyme inhibitor benazapril on the progression of chronic renal insufficiency. N. Engl. J. Med. 1996; 334: 939-45.
38. Hoy WE. Markers for cardiovascular and renal morbidity: expectations for an intervention program in an Australian Aboriginal community. Clin. Exp. Pharmacol. Physiol. 1996; 23 (Suppl 1): S33-7.